

#### Global GS1 Healthcare Conference 2016

# The new EU Medical Device Regulations: device identification and traceability

#### Salvatore Scalzo

Policy and Legal Officer European Commission DG Internal Market, Industry, Entrepreneurship and SMEs



#### **Revision of the EU Medical Devices Legislation - Background**

Directive 90/385/EEC on active implantable medical devices Directive 93/42/EEC on medical devices

**Proposal for a Regulation on medical devices** 

Directive 98/79/EC on in vitro diagnostic medical devices

Proposal for a Regulation on in vitro diagnostic medical devices



# State of play and next steps

- 26 September 2012: adoption of the two Commission proposals on medical devices and IVDs.
- 15 June 2016: Council and Parliament reached agreement on the final text
- 20 September 2016: Council's political agreement
- Early 2017 (expected): Adoption of the Council's first reading position
- Early 2017 (expected): EP second-reading vote



### Main (horizontal) features of the compromise texts 1/2

- Stricter pre-market control of high-risk devices with the involvement of a pool of experts at EU level.
- Inclusion of certain aesthetic devices within the scope.
- Reinforced designation and oversight processes of notified bodies.
- Establishment of a comprehensive EU database on medical devices (EUDAMED) and of a UDI system.
- Reinforcement of the rules on clinical evaluation (and performance evaluation) and clinical investigation (and performance studies), including introduction of a coordinated assessment of a clinical investigation conducted in more than one Member State.




### Main (horizontal) features of the compromise texts 2/2

- Improved coordination between Member States in the fields of vigilance and market surveillance.
- Stronger role for the Commission in the context of decisions on the regulatory status of products.
- Specific regime for devices manufactured and used in the same health institution.
- Clarification of the role and responsibilities of economic operators. Certain new obligations for manufacturers and authorised representatives.
- New classification system for IVDs based on international guidance.



#### **Transition period**






# Specific aspects regarding EUDAMED, UDI, traceability obligations

NB: The following slides are based on the texts agreed by the co-legislators in June 2016. Prior to final formal adoption expected in early 2017, a control of technical inconsistencies is to be done (currently ongoing).



# **EUDAMED: Processes of the Device lifecycle**





# **UDI Overview**



#### **EU UDI System:**

#### **Definition of Unique Device Identification ('UDI')**

 a series of numeric or alphanumeric characters that is created through internationally accepted device identification and coding standards and that allows unambiguous identification of specific devices on the market (Definition 13)

### Scope:

 Apply to all medical devices placed on the market except custom-made devices

#### **Approach:**

Substantially based on internationally recognised principles and guidance





# UDI issuing entities

• The European Commission shall designate UDI issuing entities provided that they satisfy certain criteria.

#### Such criteria include:

- the entity system for the assignment of UDIs is adequate to identify a device through its distribution and use in accordance with the requirements of the Regulation;
- the entity system for the assignment of UDIs conforms to the relevant international standards;
- the entity gives access to its system for the assignment of UDIs to all interested users according to a set of predetermined and transparent terms and conditions.
- Until the Commission has designated UDI issuing entities, GS1, HIBCC, ICCBBA shall be considered as designated issuing entities.





### Assignment/Submission of UDI data/UDI carrier

- Before placing a device on the market, the manufacturer shall **assign** to the device and if applicable to all higher levels of packaging a UDI.
- The **UDI carrier** shall be placed on the label of the device and on all higher levels of packaging. Higher levels of packaging do not include shipping containers.
- Before a device is placed on the market the manufacturer or his authorised representative shall ensure that the **information** referred to in Part B of Annex V of the device in question is correctly **submitted and transferred** to the UDI database
- In some cases, the manufacturer is required to assign a UDI to the device before the conformity assessment.





# Main deadlines

• UDI assignment and submission of UDI core data elements to the database: date of application of the new Regulations (unless EUDAMED is not functional by that date).

#### • UDI carrier:

- Implantable devices and Class III devices (and Class D IVDs): 1 year after the date of application.
- Class IIa and Class IIb devices (Class C and B IVDs): 3 years after the date of application;
- Class I devices (Class A IVDs): 5 years after the date of application;
- Reusable devices that shall bear the UDI Carrier on the device itself: 2 years after the date applicable for its respective class of devices.





# Requirements for Eudamed/UDI database

- Article 24 (22 IVDR) Unique Device Identification system Article 24a (22a IVDR) - Electronic system on UDI ('UDI database')
- Article 24b (22b IVDR)- Process for registration of devices (Basic UDI-DI):
- Annex V Part B Core data to be provided to the UDI database Annex V - Part C - The European Unique Device Identification System (guidance)





# Traceability-related obligations



# **Traceability obligations**

- Identification of economic operators up and down the supply chain.
- Introduction of the Single Registration Number for manufacturers, authorised representatives and importers.
- Obligation of UDI storage for all economic operators (preferably by electronic means) for Class III implantable devices (scope might be expanded through an implementing act).
- Obligation of **UDI storage for health institutions** for Class III implantable devices.



# **Towards implementation**




### **Towards implementation:** delegated/implementing acts

Implementing acts	COM Proposal total	of which compulsory	Final total	of which compulsory
MD	26	6	32	8
IVD	24	5	32	6
Delegated acts	COM Proposal total	of which compulsory	Final total	of which compulsory
MD	17	2	11	0
IVD	15	2	5	0
Total	82	13	80	14



### **Implementation: priorities**





### THANK YOU FOR YOUR ATTENTION